Ohcanbohtosat - Zonghong Shao

  • Čájehuvvo 1 - 10 / 10
Aiddostahte ozu
  1. 1
    Advances in the role of helper T cells in autoimmune diseases

    Advances in the role of helper T cells in autoimmune diseases Dahkki Xiaomei Zhang, Chunyan Liu, Zonghong Shao

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Loss of <scp>FTH1</scp> Induces Ferritinophagy‐Mediated Ferroptosis in Anaemia of Myelodysplastic Syndromes

    Loss of <scp>FTH1</scp> Induces Ferritinophagy‐Mediated Ferroptosis in Anaemia of Myelodysplastic Syndromes Dahkki Liyan Yang, Mengying Zhang, Mengyuan Liu, Yating Yu, Yue Zhang, Jinyue Yang, Limin Xing, Zonghong Shao, Huaquan Wang

    Almmustuhtton 2025
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Abnormal Ferroptosis in Myelodysplastic Syndrome

    Abnormal Ferroptosis in Myelodysplastic Syndrome Dahkki Qi Lv, Haiyue Niu, Lanzhu Yue, Jiaxi Liu, Liyan Yang, Chunyan Liu, Huijuan Jiang, Shuwen Dong, Zonghong Shao, Limin Xing, Huaquan Wang

    Almmustuhtton 2020
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    CD8+HLA-DR+ T cells are increased in patients with severe aplastic anemia

    CD8+HLA-DR+ T cells are increased in patients with severe aplastic anemia Dahkki Limin Xing, Chunyan Liu, Rong Fu, Huaquan Wang, Jun Wang, Xiao Liu, Le Feng, Lijuan Li, Hui Liu, Honglei Wang, Tian Zhang, Zonghong Shao

    Almmustuhtton 2014
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica

    Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica Dahkki Chun‐Sheng Yang, Li Yang, Ting Li, Daqi Zhang, Wei‐Na Jin, Minshu Li, Ning Su, Nannan Zhangning, Qiang Liu, Zonghong Shao, Chunshui Yu, Fu‐Dong Shi

    Almmustuhtton 2013
    Viečča ollesdeavstta
    Carta
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa‐2b

    Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa‐2b Dahkki Shanshan Suo, Rongfeng Fu, Albert Qin, Zonghong Shao, Jie Bai, Hu Zhou, Na Xu, Suning Chen, Xuelan Zuo, Xin Du, Minghui Duan, Li Wang, Pei Li, Xuhan Zhang, Sujiang Zhang, Daoxiang Wu, Jingjing Zhang, Zhijian Xiao, Lei Zhang, Jie Jin

    Almmustuhtton 2024
    Viečča ollesdeavstta
    Carta
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    Efficacy of ALK5 inhibition in myelofibrosis

    Efficacy of ALK5 inhibition in myelofibrosis Dahkki Lanzhu Yue, Matthias Bartenstein, Wanke Zhao, Wan‐Ting Ho, Ying Han, Cem Murdun, Adam W. Mailloux, Ling Zhang, Xuefeng Wang, Anjali Budhathoki, Kith Pradhan, Franck Rapaport, Huaquan Wang, Zonghong Shao, Xiubao Ren, Ulrich Steidl, Ross L. Levine, Zhizhuang Joe Zhao, Amit Verma, Pearlie K. Epling‐Burnette

    Almmustuhtton 2017
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera

    A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera Dahkki Jie Jin, Lei Zhang, Albert Qin, Daoxiang Wu, Zonghong Shao, Jie Bai, Suning Chen, Minghui Duan, Hu Zhou, Na Xu, Sujiang Zhang, Xuelan Zuo, Xin Du, Li Wang, Pei Li, Xuhan Zhang, Yaning Li, Jingjing Zhang, Wei Wang, Weihong Shen, Oleh Zagrijtschuk, Raymond Urbanski, Toshiaki Sato, Zhijian Xiao

    Almmustuhtton 2023
    Viečča ollesdeavstta Viečča ollesdeavstta
    Carta
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study

    Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study Dahkki Ningjing Lin, Mingzhi Zhang, Hai Bai, Hui Liu, Jie Cui, Xiaoyan Ke, Huilai Zhang, Lihong Liu, Dongmei Yan, Yongsheng Jiang, Aimin Zang, Junyuan Qi, Li Wang, Zhuogang Liu, Bing Xu, Ying Zhang, Zhihui Zhang, Xielan Zhao, Chunhong Hu, Shenmiao Yang, Hui Zhou, Jinsheng Shi, Zonghong Shao, Ying Xiang, Jiman Zhu, Yuqin Song, Jun Zhu

    Almmustuhtton 2021
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms

    HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms Dahkki Lanzhu Yue, Vasundhara Sharma, Nathan P. Horvat, Afua A. Akuffo, Matthew Beatty, Cem Murdun, Christelle Colin, Julia Billington, William E. Goodheart, Eva Sahakian, Ling Zhang, John J. Powers, Narmin E. Amin, Que T. Lambert-Showers, Lancia Darville, Javier Pinilla‐Ibarz, Gary W. Reuther, Kenneth L. Wright, Chiara Conti, Jennifer Y. Lee, Xiaozhang Zheng, Pui Yee Ng, Matthew W. Martin, C. Gary Marshall, John M. Koomen, Ross L. Levine, Amit Verma, H. Leighton Grimes, Eduardo M. Sotomayor, Zonghong Shao, Pearlie K. Epling‐Burnette

    Almmustuhtton 2019
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: